sc-214616

Caspase inhibitor designed as a methyl ester to facilitate cell permeability.

sc-300322

A non-peptide-based, reversible, and competitive inhibitor of caspase-3, -7 and -8 (K_i = 4.3 µM, 6.2 µM and 2.7 µM, respectively).

sc-358878

Ac-YVAD-CHO, also designated L-709049 is a potent, specific, reversible inhibitor of caspase-1 (K_i = 200 pM for human recombinant caspase-1), caspase-4, and caspase-5.

sc-300324

Ac-YVAD-AOM; a highly selective, competitive and irreversible inhibitor of caspase-1 and caspase-5.

sc-3072

Z-VDVAD-FMK. A cell-permeable, irreversible inhibitor of caspase-2.

sc-3075

A cell-permeable, potent, and irreversible inhibitor of caspase-3, caspase-6, caspase-7, and caspase-10.

sc-293986

A potent, reversible, isatin sulfonamide-based inhibitor of caspase-3 (KI(app) = 60 nM) and caspase-7 (KI(app) = 170 nM). Is a weaker inhibitor of caspase-9 (Ki(app) = 3.1 mM). Has only a trivial effect (Ki(app) >25 mM) on the activities of caspase-1, caspase-2, caspase-4, caspase-6, and caspase-8. Has been shown to inhibit apoptosis in camptothecin treated Jurkat cells (IC50 ~50 µM). Also been reported to inhibit apoptosis in chondrocytes (44% inhibition at 10 µM and 98% inhibition at 50 µM). Selectivity for caspases 3 and 7 involves unique hydrophobic residues in the S2 pocket surrounding the catalytic cysteine residue.

sc-3079

Z-VE(OMe)ID(OMe)-FMK, Inhibits caspase-6

sc-3081

Ac-AAVALLPAVLLALLAD-cho, Inhibits caspase-6

sc-3085

z-LEHD-fmk, Inhibits caspase-4,5 and 9

sc-300327

A potent and irreversible inhibitor of caspase-9 (ICE-LAP6, Mch6).

sc-224029

A potent, cell-permeable, reversible, non-competitive inhibitor of caspase-3. Also called Caspase-3 Inhibitor VII.

sc-215814

A novel tamoxifen (TAM) analog which significantly augments apoptosis-inducing effect of TAM in estrogen receptor (ER)-negatives cells. It induces mitochondria-involved apoptosis in Jurkat cells, as evidenced by chromatin-condensed cells as well as downstream activation of caspases (caspase-3, -8 and -9) in a dose- and time-dependent manner. At 4 hours of incubation, IC₅₀ for RID-B is 4 μM (30 μM for TAM). And at prolonged treatment of 48 hours, IC₅₀ for RID-B is 0.1 μM. In a related report on the global anti-tumor activity, RID-B strongly inhibits 39 human cancer cells (JFCR 39), both ER-+ or ER-- at concentrations of equal or less than 1μM (e.g., at 0.38μM for SF-539 [central nervous system], at 0.58μM for HT-29 [colon], at 0.20μM for DMS114 [lung], at 0.21μM for LOX-IMVI [melanoma], and at 0.23μM for MKN74 [stomach]. The binding protein of RID-B that exerts the apoptosis events is currently under investigation.

sc-311560